Table 3.

Summary of Placebo-Controlled Trials in Children and Adolescents with Functional Abdominal Pain Disorders

Author	Medication	N	Age	Diagnosis	Benefit vs Placebo for Abdominal Pain
Karunanayake210	Domperidone	100 (50 active drug)	5–12 years	FAP, IBS, FD	Yes in FAP only
Collins211	Rifaximin	75 (49 active drug)	8–18 years	CAP with SIBO	No
Zybach212	Melatonin	12 (cross-over)	8–17 years	FD	No
Badihian213	Buspirone	95 (48 active drug)	6–18 years	FAP	No
Sadeghian214	Cyproheptadine	29 (15 active drug)	4–16 years	FAP	Yes
See215	Famotidine	26 (12 active drug)	5–18 years	FD	Yes
Asgarshirazi158	Peppermint oil	80 (40 active drug)	4–13 years	FAP, FD, IBS	Yes
Kline216	Peppermint oil	42 (21 active drug)	8–17 years	IBS	Yes
Friesen217	Montelukast	40 (cross-over)	6–18 years	FD with eosinophilia	Yes
Narang218	Drotaverine	132 (66 active drug	4–12 years	RAP	Yes
Symon219	Pizotifen	16 (cross-over)	5–13 years	AM	Yes
Pourmoghaddas220	Mebeverine	115 (59 active drug)	6–18 years	FAP	No
Saps221	Amitriptylline	90 (46 active drug)	8–17 years	FAP, IBS, FD	No
Bahar222	Amitriptylline	33 (16 active drug)	12–18 years	IBS-D	Yes
Roohafza223	Citalopram	86 (43 active drug)	6–18 years	FAP	Yes

Abbreviations: FAP, functional abdominal pain; IBS, irritable bowel syndrome; FD, functional dyspepsia; CAP, chronic abdominal pain; SIBO, small intestinal bacterial overgrowth; RAP, recurrent abdominal pain; AM, abdominal migraine; IBS-D, diarrhea predominant irritable bowel syndrome.